GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » iSpecimen Inc (NAS:ISPC) » Definitions » Gross Profit

ISPC (iSpecimen) Gross Profit : $3.99 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is iSpecimen Gross Profit?

iSpecimen's gross profit for the three months ended in Dec. 2024 was $0.15 Mil. iSpecimen's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $3.99 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. iSpecimen's gross profit for the three months ended in Dec. 2024 was $0.15 Mil. iSpecimen's Revenue for the three months ended in Dec. 2024 was $1.48 Mil. Therefore, iSpecimen's Gross Margin % for the quarter that ended in Dec. 2024 was 10.23%.

iSpecimen had a gross margin of 10.23% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage

During the past 7 years, the highest Gross Margin % of iSpecimen was 56.20%. The lowest was 42.92%. And the median was 51.45%.

Warning Sign:

iSpecimen Inc gross margin has been in long-term decline. The average rate of decline per year is -3%.


iSpecimen Gross Profit Historical Data

The historical data trend for iSpecimen's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iSpecimen Gross Profit Chart

iSpecimen Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
Get a 7-Day Free Trial 4.60 5.89 5.65 5.11 3.99

iSpecimen Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.15 1.29 1.44 1.11 0.15

Competitive Comparison of iSpecimen's Gross Profit

For the Diagnostics & Research subindustry, iSpecimen's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iSpecimen's Gross Profit Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, iSpecimen's Gross Profit distribution charts can be found below:

* The bar in red indicates where iSpecimen's Gross Profit falls into.


;
;

iSpecimen Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

iSpecimen's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=9.291 - 5.303
=3.99

iSpecimen's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=1.476 - 1.325
=0.15

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.99 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

iSpecimen's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.15 / 1.476
=10.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


iSpecimen  (NAS:ISPC) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

iSpecimen had a gross margin of 10.23% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage


iSpecimen Gross Profit Related Terms

Thank you for viewing the detailed overview of iSpecimen's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


iSpecimen Business Description

Traded in Other Exchanges
N/A
Address
450 Bedford Street, Lexington, MA, USA, 02420
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
Executives
Benjamin Bielak officer: Chief Information Officer 450 BEDFORD STREET, LEXINGTON MA 02420
Tracy Curley officer: Chief Financial Officer 450 BEDFORD STREET, LEXINGTON MA 02420
Joseph J. Basile director 450 BEDFORD STREET, LEXINGTON MA 02420
Andrew L. Ross director, 10 percent owner 450 BEDFORD STREET, LEXINGTON MA 02420
Gullans Steven R. Ph.d. director C/O EXCEL VENTURE MANAGEMENT, LLC, 800 BOYLSTON ST., STE 2825, BOSTON MA 02199
John L Brooks director 100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090
Obf Investments, Llc 10 percent owner 450 BEDFORD STREET, LEXINGTON MA 02420
Margaret H. Lawrence director 450 BEDFORD STREET, LEXINGTON MA 02420
George H. Scholl director 450 BEDFORD STREET, LEXINGTON MA 02420
Christopher Ianelli director, officer: CEO, President 450 BEDFORD STREET, LEXINGTON MA 02420
Jill Mullan director, officer: COO, Secretary, Treasurer 450 BEDFORD STREET, LEXINGTON MA 02420